Allergy Therapeutics AI Stock Analysis
Want to see GB:AGY full AI Analyst Report?
Allergy Therapeutics (AGY) AI Stock Analysis
Allergy Therapeutics
(LSE:AGY)
The overall score of 37 reflects a company in severe financial distress with a stock in freefall. The most significant factors are the insolvent balance sheet with negative equity and the massive operational cash burn, which threaten the company's viability. This is compounded by a catastrophic technical trend, with the stock price deeply below all key moving averages and momentum at extreme oversold lows. The negative earnings make valuation metrics irrelevant. The combination of fundamental and technical collapse results in the lowest possible score.
Allergy Therapeutics (AGY) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 77.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 994.95K
- Price to Earnings (P/E)
- -1.4
- Beta (1Y)
- 0.96
- Revenue Growth
- 8.77%
- EPS Growth
- -7.14%
- Country
- UK
- Employees
- 584
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Allergy Therapeutics Business Overview & Revenue Model
Company Description
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside dia...
Allergy Therapeutics Financial Statement Overview
Summary
Financial health is critically weak. Persistent and deep net losses (-86% margin), negative stockholders' equity indicating insolvency, and severe cash burn (-37.1M free cash flow) present an existential threat. A slight revenue recovery is the only positive, but it is entirely overshadowed by the rapid deterioration in profitability, solvency, and liquidity.
Income Statement
18Very NegativeBalance Sheet
8Very NegativeCash Flow
12Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.87M | 59.87M | 55.04M | 55.20M | 59.59M | 72.77M |
| Gross Profit | 24.78M | 24.78M | 25.13M | 29.74M | 32.69M | 48.95M |
| EBITDA | -36.34M | -36.34M | -29.43M | -30.74M | -36.24M | -8.69M |
| Net Income | -51.51M | -51.51M | -40.13M | -40.22M | -43.07M | -13.78M |
Balance Sheet | ||||||
| Total Assets | 87.19M | 87.19M | 67.54M | 64.83M | 66.77M | 72.95M |
| Cash, Cash Equivalents and Short-Term Investments | 24.20M | 24.20M | 12.79M | 12.91M | 14.85M | 20.52M |
| Total Debt | 67.00M | 67.00M | 60.09M | 30.99M | 35.99M | 10.53M |
| Total Liabilities | 97.56M | 97.56M | 95.74M | 61.12M | 64.70M | 35.18M |
| Stockholders Equity | -10.37M | -10.37M | -28.19M | 3.71M | 2.07M | 37.77M |
Cash Flow | ||||||
| Free Cash Flow | -37.06M | -37.06M | -31.98M | -35.54M | -35.59M | -17.17M |
| Operating Cash Flow | -32.13M | -32.13M | -28.72M | -32.14M | -30.92M | -14.11M |
| Investing Cash Flow | -4.65M | -4.65M | -3.15M | -1.20M | -4.67M | -3.06M |
| Financing Cash Flow | 48.09M | 48.09M | 32.04M | 31.43M | 29.91M | -2.64M |
Allergy Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGY, the sentiment is Negative. The current price of 1.23 is below the 20-day moving average (MA) of 2.32, below the 50-day MA of 3.78, and below the 200-day MA of 7.35, indicating a bearish trend. The MACD of -0.81 indicates Positive momentum. The RSI at 9.64 is Positive, neither overbought nor oversold. The STOCH value of 41.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AGY.
Allergy Therapeutics Peers Comparison
Overall Rating
GB:HIK74Outperform
GB:VLG65Neutral
GB:STX43Neutral
GB:AGY37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | GBP 3.49B | 12.34 | 15.05% | 3.76% | 2.48% | 3.36% | |
| 65Neutral | GBP 81.42M | 15.71 | 7.82% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | GBP 32.76M | -4.08 | 64.57% | ― | 36.19% | 60.75% | |
| 37Underperform | GBP 77.57M | -1.39 | 1684.19% | ― | 8.77% | -7.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:AGY | Allergy Therapeutics | 1.23 | -8.08 | -86.83% | |
| GB:HIK | Hikma Pharmaceuticals | 1687.00 | 149.71 | 9.74% | |
| GB:STX | Shield Therapeutics | 3.05 | -4.65 | -60.39% | |
| GB:VLG | Venture Life | 68.50 | 10.00 | 17.09% | |
| GB:BXP | Beximco Pharmaceuticals Limited Sponsored GDR RegS | 57.50 | 20.29 | 54.52% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026
